pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

ELI LILLY CO

USupdated 4mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view ELI LILLY CO jobs →

News

  • This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
    RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmar…
    biopharma_dive · 1d ago
  • Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
    Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…
    biopharma_dive · 1d ago
  • Frazier adds $1.1B+ to small and mid-sized biotech fund
    Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for…
    biospace · 1d ago
  • Novartis drags peers down with triple asset failure
    Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
    biospace · 1d ago
  • Novartis drags peers down with triple asset stumble
    Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
    biospace · 1d ago
  • Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
    Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
    biospace · 1d ago
  • Why two promising heart drugs flopped and what’s next
    This week on "The Readout LOUD" podcast: Two experimental drugs were heralded as the next era in heart disease treatment — why did they fail?
    stat · 2d ago
  • 11 companies hiring in California now
    Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
    biospace · 2d ago
  • Merck adds 53 to New Jersey chopping block
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 2d ago
  • Kura spins diabetes work into a Lilly-backed biotech startup
    Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
    biopharma_dive · 3d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?